Skip to main content
SpringerLink
Log in

Economics of Inflammatory Bowel Disease

  • Chapter
Inflammatory Bowel Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 163 Accesses

Abstract

Advances in the medical and surgical care of patients with inflammatory bowel disease (IBD) have been geared toward improving the quality of care and quality of life of persons with this disease. Attention to cost-containment has traditionally taken a backseat to these objectives. However, in this ever-changing world of medical economics, it is reasonable to consider the economic impact of these diseases and their therapies. Economic outcomes are increasingly being requested by many parties: insurers, hospitals, the government, physicians, and, of course, the patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen RD. The cost of Crohn’s disease: drugs or surgery? BioDrugs 2000; 14: 331–44.

    Article  PubMed  CAS  Google Scholar 

  2. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309–317.

    Article  PubMed  CAS  Google Scholar 

  3. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318–327.

    Article  PubMed  CAS  Google Scholar 

  4. Hanauer SB, Cohen RD, Becker RV, 3rd, Larson LR, Vreeland MG. Advances in the management of Crohn’s disease: economic and clinical potential of infliximab. Clin Ther 1998; 20: 1009–1028.

    Article  PubMed  CAS  Google Scholar 

  5. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955–1960.

    Article  PubMed  CAS  Google Scholar 

  6. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002; 35: 151–156.

    Article  PubMed  CAS  Google Scholar 

  7. Cohen RD, Larson LR, Roth JR, Becker RV, Mummert MM. The cost of hospitalizations in Crohn’s disease. Am J Gastroenterol 2000; 95: 524–530.

    Article  PubMed  CAS  Google Scholar 

  8. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000; 95: 677–683.

    Article  PubMed  CAS  Google Scholar 

  9. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 5: 1–10.

    Article  PubMed  CAS  Google Scholar 

  10. Feagan BG. Methotrexate treatment for Crohn’s disease. Inflamm Bowel Dis 1998; 4: 120–121.

    Article  PubMed  CAS  Google Scholar 

  11. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology 1993; 104: 1293–1301.

    PubMed  CAS  Google Scholar 

  12. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 674–678.

    Article  PubMed  CAS  Google Scholar 

  13. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993; 88: 1198–1205.

    PubMed  CAS  Google Scholar 

  14. Cohen RD, Hanauer SB. Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr Op Gastroenterol 1995; 11: 321–330.

    Article  CAS  Google Scholar 

  15. Kornbluth A, Lichtiger S, Present D, Hanauer S. Long-term results of oral cyclosporin in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial. Gastroenterology 1994; 106: A714.

    Google Scholar 

  16. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 278–282.

    Article  PubMed  CAS  Google Scholar 

  17. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d’Albasio G, De Simone G, Martini N. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692–698.

    PubMed  CAS  Google Scholar 

  18. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991; 32: 1071–1075.

    Article  PubMed  CAS  Google Scholar 

  19. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn’s ileitis? J Clin Gastroenterol 1993; 17: 235–237.

    Article  PubMed  CAS  Google Scholar 

  20. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–769.

    Article  PubMed  CAS  Google Scholar 

  21. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263–1276.

    Article  PubMed  CAS  Google Scholar 

  22. Average Wholesale Prices (AWP). Vol. 2000: McKesson Wholesaler Computer Database.

    Google Scholar 

  23. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419–458.

    Article  PubMed  CAS  Google Scholar 

  24. Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997; 113: 1289–1294.

    Article  PubMed  CAS  Google Scholar 

  25. Silverstein MD, Albert DA, Hadler NM, Ropes MW. Prognosis in SLE: comparison of Markov model to life table analysis. J Clin Epidemiol 1988; 41: 623–633.

    Article  PubMed  CAS  Google Scholar 

  26. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ,et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49–57.

    Article  PubMed  CAS  Google Scholar 

  27. Korelitz B, Hanauer S, Rutgeerts P, Present D, Peppercorn M. Post-operative prophylaxis with 6-MP, 5-ASA, or placebo in Crohn’s disease: a 2 year multicenter trial. Gastroenterology 1998; 114: A1011.

    Article  Google Scholar 

  28. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 2000; 118: 264–273.

    Article  PubMed  CAS  Google Scholar 

  29. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465–1473.

    Article  PubMed  CAS  Google Scholar 

  30. Caprilli R, Andreoli A, Capurso L, Corrao G, D’Albasio G, Gioieni A, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn’s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994; 8: 35–43.

    Article  PubMed  CAS  Google Scholar 

  31. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 1617–1621.

    Article  PubMed  CAS  Google Scholar 

  32. De Dombal FT, Burton I, Goligher JC. Recurrence of Crohn’s disease after primary excisional surgery. Gut 1971; 12: 519–527.

    Article  PubMed  Google Scholar 

  33. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn’s disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818–1825.

    PubMed  CAS  Google Scholar 

  34. Sachar DB. Patterns of postoperative recurrence in Crohn’s disease. Scand J Gastroenterol-Supplement 1990; 172: 35–38.

    Article  CAS  Google Scholar 

  35. Kornbluth A, Sachar DB, Salomon P. Crohn’s Disease. In: Sleisenger, Fordtran, eds. Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Saunders, Philadelphia, PA, 1993: 1270–1304.

    Google Scholar 

  36. Greenstein AJ, Sachar DB, Pasternack BS, Janowitz HD. Reoperation and recurrence in Crohn’s colitis and ileocolitis: Crude and cumulative rates. N Engl J Med 1975; 293: 685–690.

    Article  PubMed  CAS  Google Scholar 

  37. Sachar DB, Wolfson DM, Greenstein AJ, Goldberg J, Styczynski R, Janowitz HD. Risk factors for postoperative recurrence of Crohn’s disease. Gastroenterology 1983; 85: 917–21.

    PubMed  CAS  Google Scholar 

  38. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. a long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38: 1137–1146.

    Article  PubMed  CAS  Google Scholar 

  39. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5.

    Article  PubMed  CAS  Google Scholar 

  40. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol1999; 94: 1587–1592.

    Google Scholar 

  41. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131: 497–500.

    Article  PubMed  CAS  Google Scholar 

  42. Hurst RD, Cohen RD. The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. In: Lichtenstein GR, ed. Seminars in Gastrointestinal Disease. Inflammatory Bowel Disease. Vol. 11. Philadelphia: W.B. Saunders Company, 2000: 10–17.

    Google Scholar 

  43. Fazio VW, Galandiuk S, Jagelman DG, Lavery IC. Strictureplasty in Crohn’s disease. Ann Surg 1989; 210: 621–625.

    Article  PubMed  CAS  Google Scholar 

  44. Hurst RD, Michelassi F. Strictureplasty for Crohn’s disease: techniques and longterm results. World J Surg 1998; 22: 359–363.

    Article  PubMed  CAS  Google Scholar 

  45. Michelassi F. Side-to-side isoperistaltic strictureplasty for multiple Crohn’s strictures. Dis Colon Rectum 1996; 39: 345–349.

    Article  PubMed  CAS  Google Scholar 

  46. Fazio VW, Tjandra JJ, Lavery IC, Church JM, Milsom JW, Oakley JR. Long-term follow-up of strictureplasty in Crohn’s disease. Dis Colon Rectum 1993; 36: 355–361.

    Article  PubMed  CAS  Google Scholar 

  47. Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA. Reoperative rates for Crohn’s disease following strictureplasty. Long-term analysis. Dis Colon Rectum 1996; 39: 1199–203.

    Article  PubMed  CAS  Google Scholar 

  48. Serra J, Cohen Z, McLeod RS. Natural history of strictureplasty in Crohn’s disease: 9-year experience. Can J Surg 1995; 38: 481–485.

    PubMed  CAS  Google Scholar 

  49. Reissman P, Salky BA, Edye M, Wexner SD. Laparoscopic surgery in Crohn’s disease. Indications and results. Surg Endosc 1996; 10: 1201–1203.

    Article  PubMed  CAS  Google Scholar 

  50. Ludwig KA, Milsom JW, Church JM, Fazio VW. Preliminary experience with laparoscopic intestinal surgery for Crohn’s disease. Am J Surg 1996; 171: 52–55; discussion 55–6.

    Google Scholar 

  51. Liu CD, Rolandelli R, Ashley SW, Evans B, Shin M, McFadden DW. Laparoscopic surgery for inflammatory bowel disease. Am Surg 1995; 61: 1054–1056.

    PubMed  CAS  Google Scholar 

  52. Chen HH, Wexner SD, Weiss EG, Nogueras JJ, Alabaz O, Iroatulam AJ, et al. Laparoscopic colectomy for benign colorectal disease is associated with a significant reduction in disability as compared with laparotomy. Surg Endosc 1998; 12: 1397–1400.

    Article  PubMed  CAS  Google Scholar 

  53. Wu JS, Birnbaum EH, Kodner IJ, Fry RD, Read TE, Fleshman JW. Laparoscopicassisted ileocolic resections in patients with Crohn’s disease: are abscesses, phlegmons, or recurrent disease contraindications? Surgery 1997; 122: 682–688.

    Article  PubMed  CAS  Google Scholar 

  54. Fleshman JW. Invited Editorial. Disease of the Colon and Rectum 1997; 40: 238–239.

    Google Scholar 

  55. Scott AM, Starling JR, Ruscher AE, DeLessio ST, Harms BA. Thoracic versus lumbar epidural anesthesia’s effect on pain control and ileus resolution after restorative proctocolectomy. Surgery 1996; 120: 688–695.

    Article  PubMed  CAS  Google Scholar 

  56. Grass JA. The role of epidural anesthesia and analgesia in postoperative outcome. Anesthesiol Clin North America 2000; 18: 407–428, viii.

    Google Scholar 

  57. Welch JP, Cohen JL, Vignati PV, Allen LW, Morrow JS, Carter JJ. Pain control following elective gastrointestinal surgery: is epidural anesthesia warranted? Conn Med 1998; 62: 461–464.

    PubMed  CAS  Google Scholar 

  58. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997; 32: 1134–1139.

    Article  PubMed  CAS  Google Scholar 

  59. Sonnenberg A. Disability from inflammatory bowel disease among employees in West Germany. Gut 1989; 30: 367–370.

    Article  PubMed  CAS  Google Scholar 

  60. Ferguson A, Sedgwick DM. Juvenile-onset inflammatory bowel disease: predictors of morbidity and health status in early adult life. J R Coll Physicians Lond 1994; 28: 220–227.

    PubMed  CAS  Google Scholar 

  61. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989; 34: 1379–1386.

    Article  PubMed  CAS  Google Scholar 

  62. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Impact of surgery for Crohn’s disease on health-related quality of life. Am J Gastroenterol 2000; 95: 177–182.

    Article  PubMed  CAS  Google Scholar 

  63. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 15–19.

    Article  PubMed  CAS  Google Scholar 

  64. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med 1992; 59: 35–42.

    PubMed  CAS  Google Scholar 

  65. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, S aibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287–296.

    PubMed  CAS  Google Scholar 

  66. Drossman DA, Li Z, Leserman J, Patrick DL. Ulcerative colitis and Crohn’s disease health status scales for research and clinical practice. J Clin Gastroenterol 1992; 15: 104–112.

    Article  PubMed  CAS  Google Scholar 

  67. Hjortswang H, Strom M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol 1998; 93: 2203–2211.

    Article  PubMed  CAS  Google Scholar 

  68. Moser G, Tillinger W, Sachs G, Genser D, Maier-Dobersberger T, Spiess K, Wyatt J, Vogelsang H, Lochs H, Gangl A. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 853–858.

    PubMed  CAS  Google Scholar 

  69. Meyers S, Walfish JS, Sachar DB, Greenstein AJ, Hill AG, Janowitz HD. Quality of life after surgery for Crohn’s disease: a psychosocial survey. Gastroenterology 1980; 78: 1–6.

    PubMed  CAS  Google Scholar 

  70. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 27–34.

    Article  PubMed  CAS  Google Scholar 

  71. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn’s disease. Dig Dis Sci 1995; 40: 931–935.

    Article  PubMed  CAS  Google Scholar 

  72. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, Group atAIS. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549.

    Article  PubMed  Google Scholar 

  73. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995; 332: 292–297.

    Article  PubMed  CAS  Google Scholar 

  74. Irvine EJ, Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB,. Quality of life rapidly improves with budesonide therapy for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm Bowel Dis 2000; 6: 181–187.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Russell D. Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Gastroenterology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA

    Russell D. Cohen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cohen, R.D. (2003). Economics of Inflammatory Bowel Disease. In: Cohen, R.D. (eds) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-311-8_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-311-8_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5465-0

  • Online ISBN: 978-1-59259-311-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation